Advanced in Neuroblastoma

Aurelien Marabelle

Gustave Roussy
Villejuif, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Neuroblastoma
Gustave Roussy
Villejuif, FR 
OverviewLocationsClinical Research

Overview

Aurelien Marabelle practices in Villejuif, France. Marabelle is rated as an Advanced expert by MediFind in the treatment of Neuroblastoma. Their top areas of expertise are Melanoma, Neuroblastoma, Non-Small Cell Lung Cancer (NSCLC), and Lung Cancer.

Their clinical research consists of co-authoring 287 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 14 articles and participated in 1 clinical trial in the study of Neuroblastoma.

Locations

Gustave Roussy
Villejuif, 94805, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer
Enrollment Status: Recruiting
Publish Date: March 04, 2024
Intervention Type: Genetic
Study Phase: Not Applicable
A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 31, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: June 27, 2024
Intervention Type: Drug
Study Drugs: AN0025, Pembrolizumab
Study Phase: Phase 1
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
Study Phase: Phase 1
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma
Enrollment Status: Completed
Publish Date: November 18, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours
A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours
Enrollment Status: Completed
Publish Date: October 03, 2018
Intervention Type: Drug
Study Phase: Phase 1
Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies
Immunomonitoring of Children With Neuroblastoma for the Development of Antitumor Immunotherapy Strategies
Enrollment Status: Unknown
Publish Date: August 23, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 6 Less Clinical Trials

287 Total Publications

Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Immune-related adverse events occurring rapidly after a single dose of immune checkpoint blockade.
Journal: Journal for immunotherapy of cancer
Published: August 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Marabelle's expertise for a condition
ConditionClose
      View All 9 Advanced Conditions
      View All 43 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile